Table 1 Clinical and biomarkers characteristics in amyloidosis patients by cardiac involvement (CI) and survival status
Parameters | All patients (n = 74) | With CI (n = 42) | Without CI (n = 32) | P value | Non-survivors (n = 20) | Survivors (n = 54) | P value |
|---|---|---|---|---|---|---|---|
Age (years) | 57.6 ± 10.0 | 57.8 ± 10.2 | 57.2 ± 9.9 | 0.778 | 57.0 ± 11.4 | 57.78 ± 9.5 | 0.769 |
Male (%) | 38 (51.4) | 25 (59.5) | 13 (40.6) | 0.107 | 12 (60) | 26 (48.1) | 0.365 |
BSA (m2) | 1.68 ± 0.15 | 1.68 ± 0.17 | 1.68 ± 0.12 | 0.938 | 1.66 ± 0.17 | 1.68 ± 0.14 | 0.599 |
SBP (mm Hg) | 116 ± 17 | 114 ± 18 | 119 ± 16 | 0.211 | 109 ± 15 | 119 ± 17 | 0.049 |
DBP (mm Hg) | 73 ± 12 | 71 ± 9 | 75 ± 14 | 0.226 | 69 ± 10 | 74 ± 12 | 0.102 |
HR (beats/min) | 81 ± 15 | 83 ± 15 | 78 ± 15 | 0.129 | 88 ± 13 | 78 ± 15 | 0.012 |
Mayo stage | |||||||
 I and II (%) | 43 (58.1) | 11 (26.2) | 32 (100) | < 0.001 | 7 (35) | 36 (66.7) | 0.014 |
 III and IV (%) | 31 (41.9) | 31 (73.8) | 0 (0) |  | 13 (65) | 18 (33.3) |  |
 Troponin I (ng/mL) | 0.04 (0.15) | 0.10 (0.27) | 0.01 (0.02) | < 0.001 | 0.15 (0.41) | 0.025 (0.07) | 0.003 |
 cTnT (ng/mL) | 0.03 (0.06) | 0.06 (0.11) | 0.02 (0.02) | < 0.001 | 0.10 (0.14) | 0.03 (0.04) | 0.001 |
 NT-proBNP (pg/ml) | 769 (2901) | 2436 (6514) | 348 (476) | < 0.001 | 4062 (8126) | 504 (1578) | < 0.001 |
 FLC-diff(mg/L) | 45.0 (88.2) | 75.7 (106.3) | 27.3 (57.4) | 0.111 | 100.8 (82.9) | 23.9 (87.6) | 0.094 |
 Serum creatinine (μmol/L) | 88.0 (32) | 92.5 (39.3) | 84.5 (22.3) | 0.194 | 93.5 (56.3) | 86.5 (29.8) | 0.139 |
 eGFR (ml/min/1.73m2) | 69.4 ± 23.7 | 74.0 ± 25.9 | 66.0 ± 21.6 | 0.154 | 61.6 ± 21.6 | 72.4 ± 24.1 | 0.083 |
 24 h urinary protein (g/day) | 2.27 (2.23) | 2.33 (2.75) | 2.27 (2.06) | 0.966 | 1.95 (3.19) | 2.34 (2.11) | 0.904 |